JERUSALEM, Sept. 4, 2018 /PRNewswire/ -- BiondVax
Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M-001
universal influenza vaccine candidate, reported today it will
present at the Influenza 2018 Oxford
conference at the University of
Oxford.
Joshua Phillipson, BiondVax's
Business Development Manager, will provide an overview of the
Company's clinical development achievements and plans, including
the recently launched pivotal, clinical efficacy, Phase 3
trial.
Details of Mr. Phillipson's talk:
Getting Closer to the Market: M-001 Universal Flu Vaccine
Starting Pivotal Phase 3 Trial
Date: Wednesday, September 5, 2018
Time: 10:40am
Location: Vernon Harcourt Room, South Building, St Hilda's
College, University of Oxford, UK.
About BiondVax
BiondVax (NASDAQ: BVXV) is a Phase 3
clinical stage biopharmaceutical company developing a universal flu
vaccine. The vaccine candidate, called M-001, is designed to
provide multi-season protection against current and future,
seasonal and pandemic influenza virus strains. BiondVax's
proprietary technology utilizes a unique combination of conserved
and common influenza virus peptides, activating both arms of the
immune system for a cross-protecting and long-lasting effect. In a
total of 6 completed Phase 1/2 and Phase 2 human clinical trials,
covering 698 participants, the vaccine has been shown to be safe,
well-tolerated, and immunogenic.
Please visit www.biondvax.com.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties reflect the management's
current views with respect to certain current and future events and
are subject to various risks, uncertainties and assumptions that
could cause the results to differ materially from those expected by
the management of BiondVax Pharmaceuticals Ltd. Risks
and uncertainties include, but are not limited to, the
prosecution and outcome of the ongoing Phase 2 and Phase 3 trials
and any subsequent trials; timing of receipt of regulatory
approval of the new manufacturing facility its products; ability to
demonstrate the efficacy and safety of the vaccine; the timing of
clinical trials and marketing approvals; the risk that drug
development involves a lengthy and expensive process with uncertain
outcome; the ability of the Company to maintain, preserve and
defend its intellectual property and patents granted; whether
our vaccine candidate will successfully advance through the
clinical trial process on a timely basis, or at all, and receive
approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; the
adequacy of available cash resources and the ability to raise
capital when needed. More detailed information about the risks
and uncertainties affecting the Company is contained under the
heading "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2017 filed
with the U.S. Securities and Exchange Commission, or SEC, which is
available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC and the Tel-Aviv Stock
Exchange. We undertake no obligation to revise or update any
forward-looking statement for any reason.
Contact Details
Joshua E.
Phillipson
+972 8 930 2529
j.phillipson@biondvax.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/biondvax-to-present-at-influenza-2018-oxford-conference-300706074.html
SOURCE BiondVax Pharmaceuticals Ltd.